# China limits biotech platform exports as MOFCOM targets cell therapy *The Ministry of Commerce bans overseas ownership transfers of cell and gene therapy platforms while preserving contract manufacturing and out-licensing deals.* **Published:** October 23, 2026 **By:** Hao Feng **Section:** Trade & Industrial Policy — China **Format:** Policy Tracker **Confidence:** high **Source:** https://eastasiabrief.com/trade-policy/china-limits-biotech-platform-exports-mofcom-targets-cell-therapy-880 **Publisher:** East Asia Brief (https://eastasiabrief.com/) --- ## What to know - MOFCOM draft export rule bans overseas ownership transfers of cell and gene therapy platforms - Chinese firms executed $110 billion in biopharma licensing across 81 deals in the first half of 2026 - Comment period closes Nov. 15, 2026, following immediate pre-export registration enforcement ![A researcher wearing a mask and gloves works with a pipette near a bioreactor in a biotechnology laboratory. (AI-generated image)](https://eastasiabrief.com/media/2026-10-23-f6e1226bda24.webp) *A researcher wearing a mask and gloves works with a pipette near a bioreactor in a biotechnology laboratory. (AI-generated image)* China's Ministry of Commerce on Oct. 23, 2026, advanced draft export controls restricting five sensitive biotechnology platforms, targeting outbound transfers of cell and gene therapies while subjecting active deals to immediate pre-export registration. The measure stems from Announcement No. 48 of 2026, issued jointly by the commerce ministry and the Ministry of Science and Technology. The agencies oversee cross-border technology transfers under the Foreign Trade Law. The restrictions target proprietary technologies supporting cell and gene therapies, small interfering RNA drugs and pathogenic microorganisms. Chinese drug developers struck 81 outbound licensing transactions worth $110 billion during the first half of 2026 alone. The draft revises China's Catalogue of Technologies Prohibited or Restricted from Export. The catalogue functions as the central regulatory list determining which industrial know-how and advanced equipment cannot cross borders without state approval. The biopharma provisions establish a clear legal boundary between technology ownership and commercial operation. Outright transfers of ownership in foundational drug discovery platforms to foreign buyers are placed under a complete prohibition. Foundational platforms are defined as reusable systems built through sustained research that support multiple drug assets. Proprietary discovery and validation technologies for completely new therapeutic targets are designated as restricted technologies, requiring government export approvals. The ministry explicitly exempted transactional licensing agreements where underlying platform ownership remains in Chinese hands. Outbound licensing, academic partnerships and clinical collaborations for single drug molecules can proceed through expedited administrative clearance. Contract research, development and manufacturing organizations also fall outside the ownership ban. Domestic providers of contract development and manufacturing services (CDMO) may continue utilizing proprietary platforms to formulate therapies for foreign pharmaceutical clients. The regulatory framework shields China's export-oriented biopharma supply chain while keeping domestic intellectual property onshore. International pharmaceutical groups have expanded their reliance on Chinese laboratories to discover next-generation oncology and rare-disease candidates. WuXi Biologics books more than 70% of its revenue from overseas clients that rely on Chinese development suites for complex biologics. The exemption for service contracts prevents immediate cancellations across international manufacturing pipelines. Global drugmakers such as AstraZeneca and Pfizer have secured multi-billion-dollar licensing pacts with Chinese biotechs over the past two years. Those programs remain viable because the overseas partners acquire product commercial rights rather than the underlying technology platform. The ministries simultaneously instituted a mandatory pre-export registration mechanism that took effect immediately upon publication. Technology exporters must log proposed cross-border transactions through the ministry's unified trade platform before executing transfer agreements. The pre-export registration requirement also applies to pending transactions that have started but remain incomplete. Chinese life-science ventures pursuing cross-border corporate restructuring or initial public offerings overseas now face statutory disclosure obligations. Corporate restructurings that shift intellectual property ownership to offshore corporate shells are now caught under the transfer ban. The provision curtails the popular "NewCo" corporate model, where domestic biotechs spin off core assets into overseas entities backed by foreign venture funds. South Korea's Samsung Biologics operates 604,000 liters of biomanufacturing capacity in Songdo, positioning its contract manufacturing operations to absorb international clients seeking untangled intellectual property. Incheon-based biomanufacturers have observed heightened inquiries from global sponsors looking to diversify clinical-phase production away from Chinese facilities. The notice does not state whether specialized synthetic biology DNA synthesis printers are classified under pathogenic equipment provisions, and the ministry has not published specific parameter thresholds for bioreactor systems. Public comments on Announcement No. 48 close on Nov. 15, 2026, after which the ministries will finalize the export catalogue and implement formal administrative licensing procedures. ## Impact map | Event | Korea | China | Japan | Global impact | | --- | --- | --- | --- | --- | | Biotech platform export controls | Samsung Biologics captures Western CDMO demand diverted from Chinese platform risks | WuXi Biologics retains CDMO service channel while overseas asset transfers are blocked | Chugai and Takeda maintain licensing channels under automatic registration exemptions | Big pharma adapts deal structures from equity buyouts to asset licensing | | Biotech platform export controls | Samsung Biologics captures Western CDMO demand diverted from Chinese platform risks | WuXi Biologics retains CDMO service channel while overseas asset transfers are blocked | Chugai and Takeda maintain licensing channels under automatic registration exemptions | Big pharma adapts deal structures from equity buyouts to asset licensing | ## In this story - **Companies:** WuXi Biologics, Samsung Biologics - **Tickers:** 2269.HK, 207940.KS - **Exposed:** AstraZeneca, Pfizer - **Policy:** Export Controls - **Impact:** Compliance, Supply Chain, Order Book ## Primary sources 1. mofcom.gov.cn 2. ropesgray.com 3. geneonline.com 4. allsci.com 5. hankunlaw.com --- Cite as: East Asia Brief, "China limits biotech platform exports as MOFCOM targets cell therapy," October 23, 2026. https://eastasiabrief.com/trade-policy/china-limits-biotech-platform-exports-mofcom-targets-cell-therapy-880